FDA Approves Pfizer’s Zavzpret in Acute Treatment of Migraine
The FDA has approved Pfizer’s Zavzpret (zavegepant), a nasal spray for acute treatment of adults with migraine, with or without aura.
The nasal spray, which provides pain relief in as little as 15 minutes, offers an alternative for patients who are unable to take oral medications due to the nausea and vomiting that can accompany migraine.
Zavzpret is one of a new class of drugs that works by blocking calcitonin gene-related peptide (CGRP), a protein that plays a role in the development of migraine.
The agency approval was supported by data from a late-stage trial showing the treatment led to freedom from pain and significant symptoms at two hours post-dose.
Pfizer plans to make the drug available in pharmacies in July.
March 13, 2023
https://www.fdanews.com/
The nasal spray, which provides pain relief in as little as 15 minutes, offers an alternative for patients who are unable to take oral medications due to the nausea and vomiting that can accompany migraine.
Zavzpret is one of a new class of drugs that works by blocking calcitonin gene-related peptide (CGRP), a protein that plays a role in the development of migraine.
The agency approval was supported by data from a late-stage trial showing the treatment led to freedom from pain and significant symptoms at two hours post-dose.
Pfizer plans to make the drug available in pharmacies in July.
March 13, 2023
https://www.fdanews.com/
